Las Vegas, NV -- (SBWIRE) -- 12/10/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), ReneSola Ltd. (ADR) (NYSE:SOL), Coronado Biosciences Inc (NASDAQ:CNDO), Equal Energy Ltd. (USA) (NYSE:EQU)
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) managed to keep its gain at 16.46% on above-normal volume of 5.34M shares. The stock settled at $6.65 after floating in a range of $6.12 to $7.48. Its latest price has reached market capitalization of $270.92 million. Its 52-week range has been $2.03 to $7.48. Prana Biotechnology Limited (Prana) is development stage company. The Company is engaged in develop therapeutic drugs designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses, initially focusing on Alzheimer’s disease. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company is also focusing on Huntington’s and Parkinson’s diseases.
For How Long PRAN will fight for Profitability? Read This Trend Analysis report
ReneSola Ltd. (ADR) (NYSE:SOL) traded down on a volume of 5.19 million, higher than its standard daily volume. Shares have dropped-0.99% to $2.99. Over the last twelve months, the stock has gained 121.48% and faced a worst price of $1.25. ReneSola Ltd (ReneSola), incorporated on March 17, 2006, is a global manufacturer of solar wafers and producer of solar power products based in the People's Republic of China. ReneSola possess a global network of suppliers and customers that includes some of the global manufacturers of solar cells and modules.
Has SOL Found The Bottom And Ready To Gain Momentum? Find Out Here
Coronado Biosciences Inc (NASDAQ:CNDO) settled 13.37% higher at $1.95 on above-normal volume of 3.84M shares during the last trading day. The stock has its 12-month high at $12.70 and 52-week low price was $1.25. It traded in a range of $1.72 to $1.95 during the last trading day. Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include TSO or CNDO-201, which is a biologic comprising Trichuris suis ovathe, the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn?s disease, ulcerative colitis, multiple sclerosis.
Why Should Investors Buy CNDO After the Recent Fall? Just Go Here and Find Out
In the last trading session, Equal Energy Ltd. (USA) (NYSE:EQU) showed no change on high volume, trading at a volume of 4.59M versus its average daily volume of 199,315.00 shares. At $5.37, the stock has attained market capitalization of 191.32 million. Equal Energy Ltd. engages in the acquisition, exploration, development, and production of petroleum and natural gas properties in Canada. The company has producing properties principally in Lincoln, Logan, and Jefferson counties of Oklahoma. Its products include crude oil, natural gas liquids, and natural gas. The company was founded in 1998 and is headquartered in Calgary, Canada.
Can EQU Show a Strong Recovery? Find out in This Research Report
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)